Demystifying DexCom: Insights From 15 Analyst Reviews
Portfolio Pulse from Benzinga Insights
DexCom (NASDAQ:DXCM) has received mixed ratings from 15 analysts over the past three months, with a notable decline in price targets. The average 12-month price target is now $107.6, down from $145.07. Analysts have predominantly lowered their ratings and price targets, reflecting changing market dynamics and company performance.
July 29, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
DexCom has received mixed ratings from analysts, with a significant decline in price targets. The average 12-month price target is now $107.6, down from $145.07. Analysts have predominantly lowered their ratings and price targets, reflecting changing market dynamics and company performance.
The majority of analysts have lowered their ratings and price targets for DexCom, indicating a bearish sentiment. This is likely to put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100